Abstracts tagged "anti-TNF therapy"

Abstract Number: 2591 • 2016 ACR/ARHP Annual Meeting
Association Between Flare and Radiographic Progression in Patients with Rheumatoid Arthritis
Josef Smolen¹, Heather Jones², Ehab Mahgoub², Ronald Pedersen³ and Lisa Marshall², ¹Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ³Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Biologic therapy has improved RA management and enabled some patients to achieve remission. Many clinicians decrease the biologic dose for patients in low disease…
Abstract Number: 611 • 2016 ACR/ARHP Annual Meeting
Analysis of a German Subpopulation with Active Rheumatoid Arthritis Treated with Golimumab As Add-on Therapy to Disease-Modifying Antirheumatic Drugs
Hendrik Schulze-Koops¹, Jürgen Wollenhaupt², Marita Winnemöller³, Ines Klaudius³ and Helena Löffler³, ¹Division of Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ³Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: In previous clinical studies the human monoclonal TNFα-antibody golimumab (GLM) showed a good clinical response and a favorable benefit:risk profile in the treatment of…
Abstract Number: 1596 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors
Leslie R. Harrold^1,2, George W. Reed^1,2, Jennie Best³, Steve Zlotnick³, Gioia Persuitte² and Joel M. Kremer⁴, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴The Albany Medical College, Albany, NY
Background/Purpose: Clinical studies have demonstrated the superior efficacy of tocilizumab monotherapy (TCZ mono) to tumor necrosis factor inhibitor (TNFi) monotherapy and the comparable efficacy of…
Abstract Number: 2592 • 2016 ACR/ARHP Annual Meeting
The Impact of Biologic Therapy Introduction on Hip and Knee Replacement Among Rheumatoid Arthritis Patients: An Interrupted Time Series Analysis Using the Clinical Practice Research Datalink
Samuel Hawley¹, René Cordtz², Lene Dreyer³, Christopher J. Edwards⁴, Nigel K Arden⁵, Antonella Delmestri⁵, Cyrus Cooper^1,6, Andrew Judge⁵ and Daniel Prieto-Alhambra⁷, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ²Dept. of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ³Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ⁴University of Southampton, Southampton, United Kingdom, ⁵Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁶Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁷Internal Medicine and Primary Care, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol i Gurina-Institut Català de la Salut; Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Barcelona, Spain
Background/Purpose: In several developed countries it has been observed that the incidence of orthopaedic surgery among rheumatoid arthritis (RA) patients has been in decline, despite…
Abstract Number: 613 • 2016 ACR/ARHP Annual Meeting
Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients
Alejandro Balsa¹, Raimon Sanmarti², José Rosas³, Susana Gomez Castro⁴, Ana Cabez⁴, Victor Martin⁴ and María Montoro⁴, ¹Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴Pfizer, Madrid, Spain
Abstract Immunogenicity of anti-TNF therapies in Patients with inflammatory rheumatic Diseases and secondary failure: a multicentre study of 570 patients. Background/Purpose: The treatment of…
Abstract Number: 1674 • 2016 ACR/ARHP Annual Meeting
Do TNF Inhibitors Change the Progression of Sacroiliitis?
Deeba Minhas¹, MinJae Lee^2,3, Mohammad H. Rahbar³, Lianne S. Gensler⁴, John D. Reveille⁵ and Michael Weisman¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Medicine, University of Texas Health Science Center at Houston, Houston, TX, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴Medicine/Rheumatology, UCSF, San Francisco, CA, ⁵Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting the sacroiliac (SI) joints and spine causing structural changes seen on clinical radiography. Studies have…
Abstract Number: 2602 • 2016 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Gaetane Nocturne^1,2, Bineta Ly³, Saida Boudaoud⁴, raphaèle seror^5,6, Laurence Zitvogel⁷ and Xavier Mariette^8,9, ¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ²INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, ³INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁴INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, ⁵Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ⁶INSERM U1184, Paris Sud University, Le Kremlin Bicetre, France, ⁷IGR - INSERM U1015, Villejuif, France, ⁸Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, ⁹INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of lymphoma linked to activity of the disease. Immunosuppressive drugs have been suspected to induce…
Abstract Number: 63 • 2016 ACR/ARHP Annual Meeting
Identification of Immune Gene Modules in Good Responders to Adalimumab in Rheumatoid Arthritis
James OIiver¹, Darren Plant², Gisela Orozco¹, Samantha Smith¹, Kimme L. Hyrich³, Ann Morgan⁴, John Isaacs⁵, Anthony G. Wilson⁶ and Anne Barton^1,2, ¹Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust, Manchester, United Kingdom, ³Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁵Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁶UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland
Background/Purpose: Despite the revolutionary impact of TNF inhibitor (TNFi) therapy in rheumatoid arthritis (RA), up to 40% of patients fail to respond adequately. Whilst non-responder…
Abstract Number: 618 • 2016 ACR/ARHP Annual Meeting
Do Canadian Rheumatologists Actually Treat to Target Once a Biologic Has Been Initiated? an Analysis from a Prospective, Observational Registry
Philip Baer¹, Andrew Chow², Michael Starr³, Boulos Haraoui⁴, Regan Arendse⁵, Michelle Teo⁶, Emmanouil Rampakakis⁷, Eliofotisti Psaradellis⁸, Allen J Lehman⁹, Francois Nantel¹⁰, Brendan Osborne¹¹, Cathy Tkaczyk¹¹ and Karina Maslova⁹, ¹Independent Rheumatology Practice, Scarborough, ON, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Balfour Medical Clinic, Penticton, BC, Canada, ⁷JSS Medical Research, St-Laurent, QC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Janssen Inc., Toronto, ON, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Methods: Results: After 6 months of treatment, 46% of patients had achieved treatment target of remission or low DA, and 54% were…
Abstract Number: 1695 • 2016 ACR/ARHP Annual Meeting
Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response
Meghna Jani¹, Hector Chinoy², Anne Barton² and on behalf of OUTPASS, ¹Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Up to 40% of patients with inflammatory arthritis on TNF-α inhibitor (TNFi) treatment fail to respond either due to primary inefficacy or loss of…
Abstract Number: 2617 • 2016 ACR/ARHP Annual Meeting
Economic Burden of Non-Responders to Biologic DMARD Treatments in Rheumatoid Arthritis
Vibeke Strand¹, Namita Tundia², Yan Song³, Dendy Macaulay⁴ and Mahesh Fuldeore⁵, ¹School of Medicine, Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²AbbVie, Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Analysis Group, Inc., New York, NY, ⁵AbbVie, Inc, North Chicago, IL
Background/Purpose: Biologic agents are effective in treating patients with rheumatoid arthritis (RA); however, some patients either fail to respond or lose response over time. This…
Abstract Number: 556 • 2015 ACR/ARHP Annual Meeting
Induction-Maintenance in Early RA: A Meta-Analysis of Trials Using MTX Plus Adalimumab As Induction Therapy
Sharzad Emamikia¹, Elizabeth V. Arkema², Noémi Györi¹, Jacqueline Detert³, Katerina Chatzidionysiou¹, Maxime Dougados⁴, Gerd Burmester⁵ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Paris-Descartes University, Paris, France, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The goal of rheumatoid arthritis (RA) treatment is remission or, when not achievable, low-disease-activity (LDA). Initial combined therapy with MTX + anti-TNF achieves these…
Abstract Number: 1042 • 2015 ACR/ARHP Annual Meeting
Pragmatic Multicenter Open-Label Randomized Controlled Trial of Stopping TNF-Inhibitors in Rheumatoid Arthritis Patients in Remission or Stable Low Disease Activity in the Netherlands
Marjan Ghiti Moghadam¹, Harald E. Vonkeman², Peter M. ten Klooster³, Janneke Tekstra⁴, Dirkjan van Schaardenburg⁵, Mirian Starmans-kool^6,7, Elisabeth Brouwer⁸, Reinhard Bos⁹, Willem F. Lems¹⁰, Edgar Colin¹¹, Cornelia F. Allaart¹², Inger L. Meek¹³, Robert B.M. Landewé¹⁴, Hein J. Bernelot Moens¹⁵, Piet van Riel¹³, Mart A.F.J. van de Laar¹⁶, Tim Jansen¹⁷ and on behalf of the Dutch National POET Collaboration., ¹rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Jan van Breemen Research Institute, Amsterdam, Netherlands, ⁶Rheumatology, Orbis Medical Center, Geleen-Sittard, Netherlands, ⁷Rheumatology, Atrium Medical center, Heerlen, Netherlands, ⁸Rheumatology, University Medical center Groningen, Groningen, Netherlands, ⁹Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ¹⁰Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ¹¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ¹²Department of Rheumatology, Leiden Universitary Medical Center, Leiden, Netherlands, ¹³Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹⁵rheumatology, Ziekenhuisgroep Twente, Almelo, Netherlands, ¹⁶Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ¹⁷VieCuri Medical Center, Venlo, Netherlands
Background/Purpose: TNF-inhibitors (TNFi) are effective treatments of rheumatoid arthritis (RA). It is not clear if patients in remission or stable low disease activity need to…
Abstract Number: 1989 • 2015 ACR/ARHP Annual Meeting
Treatment of Refractory Non-Infectious Aortitis: Tocilizumab Compared to Antitnf Alfa Agents. Multicenter Study of 44 Patients
Montserrat Santos-Gómez¹, Javier Loricera¹, Ricardo Blanco¹, Jose L. Hernández², Santos Castañeda³, Norberto Ortego-Centeno⁴, M. Enriqueta Peiró¹, Paz Collado⁵, Sheila Melchor⁶, Antonio Mera⁷, Eva Pérez-Pampin⁸, Esteban Rubio Romero⁹, Jaime Calvo-Alen¹⁰, Elena Aurrecoechea¹¹, Iñigo Rúa-Figueroa¹², Mauricio Minguez¹³, Gabriel Herrero-Beaumont¹⁴, Beatriz Bravo¹⁵, José Rosas¹⁶, Javier Narváez¹⁷, Javier Calvo¹⁸, Rafael Ariza-Ariza¹⁹, Mercedes Freire²⁰, Pablo Lluch Mesquida²¹, Cristina Mata²², Eva Galindez-Agirregoikoa²³, Juan María Blanco Madrigal²³, Amalia Sánchez²⁴, José Salvatierra²⁵, Vanesa Calvo-Río¹, Carmen Gonzalez-Vela²⁶, Natalia Palmou¹, Leyre Riancho-Zarrabeitia¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario de la Princesa, Madrid, Spain, ⁴Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ⁵Rheumatology, Pediatric Rheumatology Unit, Hospital Universitario Severo Ochoa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Hospital Universitario de Santiago de Compostela, La Coruña, Spain, ⁸Rheumatology, Hospital Universitario de Santiago de Compostela, La coruña, Spain, ⁹Rheumatology Department,, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁰Rheumatology Division, Hospital de Sierrallana, Torrelavega, Spain, ¹¹Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ¹²Rheumatology, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canarias, Spain, ¹³Department of Rheumatology, Hospital Universitario San Juan, Alicante, Spain, ¹⁴Department of Osteoarticular Pathology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ¹⁵Pediatric rheumatology, Hospital Virgen de las Nieves, Granada, Spain, ¹⁶Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ¹⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁸Rheumatology, Hospital General Consorcio de Valencia, Valencia, Spain, ¹⁹Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ²⁰Rheumatology, Complejo Hospitalario Universitario de A Coruña, La Coruna, Spain, ²¹Hospital Mateu Orfila, Mahón (Menorca), Spain, ²²Rheumatology, Hospital de Sierrallana, Laredo, Spain, ²³Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ²⁴Hospital Lucus Augusti, Lugo, Spain, ²⁵Hospital Universitario de San Cecilio, Granada, Spain, ²⁶Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Aortitis is often refractory to conventional immunosuppressive (IS) therapy. The use of biological therapy, such as tocilizumab (TCZ) and anti-TNFα agents have been…
Abstract Number: 2854 • 2015 ACR/ARHP Annual Meeting
Long-Term Tolerability and Efficacy of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results from the Open-Label Extension of a Randomized, Double-Blind Study
Désirée van der Heijde¹, Maxime Dougados², Walter Maksymowych³, Gina Bergman⁴, Sean P. Curtis⁴, Anjela Tzontcheva⁴, George Philip⁴, Susan Huyck⁴ and Joachim Sieper⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Paris-Descartes University, Paris, France, ³University of Alberta, Edmonton, AB, Canada, ⁴Merck & Co., Inc., Kenilworth, NJ, ⁵University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: The tolerability and efficacy of golimumab (GLM) as a treatment for nonradiographic axial spondyloarthritis (nr-axSpA) were recently investigated in a randomized, double-blind (DB), placebo…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].